We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2019 to May 2024
By Carlo Martuscelli
Clinical-stage biotechnology business Immatics said Thursday that GlaxoSmithKline will license two of its T-cell therapy candidates being developed to treat cancer for a $50 million upfront payment.
Under the terms of the agreement, Glaxo will be responsible for developing, manufacturing and commercializing the investigative treatments. Immatics said that, in addition to the award upfront, is eligible for over $550 million in development, regulatory and commercial payments for each product, plus royalties.
The collaboration deal also includes the option for the British pharmaceutical company to license additional candidates. German biotech startup Immatics said that it is developing treatments that uses natural or engineered T-cells, a kind of immune cell, to fight solid tumors.
This latest deal brings Glaxo's cell-therapy pipeline up to six assets, from four previously. In Europe there are currently two approved cell-therapy products, both to treat certain blood cancers, developed by drug makers Gilead Science and Novartis.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu
(END) Dow Jones Newswires
February 20, 2020 05:14 ET (10:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
